槐耳颗粒联合化疗治疗复发性晚期非小细胞肺癌的临床观察 吴飞雪宇明慧许晓洲 (安徽中医学院第一附属医院肿瘤科,合肥 230031) 摘要:目的晚期复发的非小细胞肺癌治疗效果差,可选择的药物不多。探讨槐耳颗粒联合培美曲塞和顺铂治疗晚期复发性非小细 胞肺癌(NSCLC)的疗效及不良反应。方法经病理学或细胞学确诊的晚期复发性非小细胞肺癌患者 16 例。其中男性 9 例,女性 7 例,中位年龄 57 岁。KPS 评分≥70。槐耳颗粒 20mg 口服每日 3 次,培美曲塞 500mg/ m2 第 1 天+顺铂 75mg/m2 分次给予(第 1~3 天), 每 3 周重复。至少 2 周期以上,可评价疗效及不良反应。结果无 CR 病例,PR5 例,SD7 例,PD4 例,RR 为 %(5/16),DCR 为 75%(12/16);生活治疗改善率 %(13/16)。主要不良反应是骨髓抑制和胃肠道反应。结论槐耳颗粒联合培美曲塞和顺铂治 疗晚期复发性非小细胞肺癌疗效确切,不良反应发生率低,耐受性较好。 关键词:槐耳颗粒;复发;晚期非小细胞肺癌 doi:.1672- 文章编号:1672-2779(2012)-06-0017-03 Huaier bination Chemotherapy Treatment for Recurrent Advanced Non-small-cell Lung Cancer Clinical Research Wu Feixue Yu Minghuei Xu Xiaozhout (The Department of Oncology, The First Affiliated Hospital of Anhui College of Traditional Chinese Medicine, Anhui hefei 230031, China) Abstract: Objective The treatment effect of advanced recurrent non-small cell lung cancer (NSCLC) is poor, and there are not enough kinds of medicine for treating. The purpose of this study was evaluate the efficacy huaier bined with pemetrexed and cisplatin in the treatment of advanced recurrent NSCLC. Methods The study was conducted on sixteen patients with advanced NSCLC who had failed to previous chemotherapy and all these patients had been confirmed with pathology or cytol
